SCM
BNTC icon

Sterling Capital Management’s Benitec Biopharma BNTC Stock Holding History

Sterling Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34K Buy
126
+29
+30% +$336 ﹤0.01% 3051
2025
Q4 		$1.31K Buy
97
+61
+169% +$844 ﹤0.01% 3117
2025
Q3 		$505 Buy
36
+1
+3% +$13 ﹤0.01% 3159
2025
Q2 		$410 Buy
+35
New +$490 ﹤0.01% 3175

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sterling Capital Management's BNTC Position: Q1 2026 in Review

Sterling Capital Management increased its Benitec Biopharma (BNTC) stake by 30% in Q1 2026, buying an estimated $336 and bringing the position to 126 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

Sterling Capital Management first reported a position in BNTC in Q2 2025 and has held it in 4 quarters since. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Sterling Capital Management held 126 shares of Benitec Biopharma worth $1.34K as of Q1 2026.
  • Sterling Capital Management bought 29 Benitec Biopharma shares in Q1 2026, an estimated $336.
  • Benitec Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3051 holding.
  • Sterling Capital Management first reported a position in Benitec Biopharma in Q2 2025 and has held it in 4 quarters since.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.